The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted Nigerians, particularly healthcare providers, to one batch of counterfeit Meronem 1g injection in circulation.
Meronem (Meropenem trihydrate injection) is an antibiotic used to treat skin and abdominal infections caused by bacteria and meningitis in adults and children three months of age and older.
In a public alert signed by Mojisola Adeyeye, NAFDAC director-general, the agency said Pfizer, the marketing authorisation holder (MAH), reported the incident.
According to the alert, Pfizer said it was informed through a patient notification platform, about a suspicious pack of Meronem 1g injection purchase.
Pfizer said the vial content did not dissolve when reconstituted for use, and that on further visual inspection of the pack, it was observed that the crimp code does not match the code reported on the production documentation batch of 2A21F11 — which is the semi-finished batch used for 4A21I17.
“The batch number and expiry date match an authentic batch of Meronem 1g injection intended for distribution in the Egyptian market. The vial label compares favourably to the purported artwork version,” the alert reads.
“The administration of the counterfeit product will pose a high risk to patients as the quality and safety are not guaranteed.
“Healthcare providers and patients are advised to obtain all medical products from authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked before purchase and administration.
“All importers, wholesalers and retailers are implored to maintain vigilance within the supply chain and desist from illegal importation, distribution, and sale of the counterfeit Meronem 1g injection and other counterfeit and substandard medicinal products.
“Anybody possessing the counterfeit product should stop using it and submit it to the nearest NAFDAC office.
“Seek immediate medical advice from a qualified healthcare professional if you have used the product, or you suffered an adverse reaction/event having used the product.
“Healthcare professionals and consumers are advised to report any suspicion of adverse drug reactions, or substandard and falsified medicines to the nearest NAFDAC office, NAFDAC 0800-162-3322 or via email: [email protected].”(The Cable)
